Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study

Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on the ruxolitinib cream (Opzelura) for treating children ... Read More